Casein Peptide Composition for Diabetes Incidence Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases like diabetes mellitus, particularly type 1 and type 2 diabetes, are inadequate in maintaining long-term glycemic control and are associated with unwanted side effects, necessitating a safe and effective nutritional composition to reduce the incidence of these diseases.
Innovation Solution
A nutritional composition comprising a peptide component, specifically a protein hydrolysate with a molar mass distribution greater than 500 Daltons, derived from extensively hydrolyzed casein, which is administered to target subjects to reduce the incidence of diabetes mellitus by modulating immune responses and improving glycemic control.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for autoimmune diseases like diabetes mellitus are used, then glycemic control may be achieved, but unwanted side effects occur and long-term control is inadequate
Solution Approach 1:
The patent changes the molecular weight parameter of the peptide component to greater than 500 Daltons, which fundamentally alters the immune system's recognition and response to the peptide. This parameter change enables the peptide to resist degradation and avoid triggering harmful autoimmune responses while maintaining its functional benefits for glycemic control
Solution Approach 2:
The peptide component acts as an intermediary substance that modulates immune responses without directly causing harm. It serves as a bridge between the immune system and glycemic control mechanisms, providing protective effects against autoimmune diseases while improving diabetes management without the side effects of conventional treatments
2Reliability
If protein hydrolysate is used in nutritional composition, then immune response modulation is achieved, but peptides with low molecular weight may trigger autoimmune responses
Solution Approach 1:
The critical parameter changed is the molecular weight distribution of peptides, specifically ensuring all peptides exceed 500 Daltons. This parameter threshold prevents the immune system from recognizing these peptides as foreign antigens, thereby modulating immune responses beneficially without triggering harmful autoimmune reactions
Solution Approach 2:
The patent applies local quality by ensuring that all peptide components within the hydrolysate meet the minimum molecular weight criterion of 500 Daltons. This localized quality control at the molecular level throughout the entire composition prevents autoimmune triggering while maintaining immune modulation benefits
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present disclosure relates to nutritional compositions including a protein equivalent source including a peptide component comprising selected peptides from Tables 1 and 2 disclosed herein. The protein equivalent source may further include intact protein, hydrolyzed protein, including partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of reducing the incidence of autoimmune disease and/or diabetes mellitus by providing said nutritional compositions to a target subject, which includes a pediatric subject.